Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$223 Mln
P/E Ratio
--
P/B Ratio
0.96
Industry P/E
--
Debt to Equity
1.09
ROE
-0.43 %
ROCE
-22.75 %
Div. Yield
0 %
Book Value
6.14
EPS
-3.02
CFO
$-340.96 Mln
EBITDA
$-682.59 Mln
Net Profit
$-623.08 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nevro (NVRO)
| 55.38 | 1.23 | 61.00 | -58.36 | -56.58 | -40.92 | -19.41 |
|
BSE Sensex
| -2.43 | 0.54 | -3.62 | 6.02 | 9.68 | 21.97 | 10.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Nevro (NVRO)
| -82.46 | -45.66 | -51.15 | -53.17 | 47.27 | 202.24 | -43.49 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 16.29 | 11,350.65 | 16.03 | 12.69 | |
| 73.91 | 9,922.23 | 95.45 | 2.52 | |
| 169.50 | 9,319.12 | -- | -25.23 | |
| 281.33 | 10,500.20 | 778.91 | 1.2 |
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza... SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California. Address: 1800 Bridge Parkway, Redwood City, CA, United States, 94065 Read more
Senior VP & CFO
Mr. Roderick H. MacLeod
President, CEO & Director
Mr. Kevin R. Thornal
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nevro Corp (NVRO) stood at $ 554 Mln as on 31-Dec-24
The share price of Nevro Corp (NVRO) is $5.78 (NYSE) as of 20-Mar-2025 16:10 EDT. Nevro Corp (NVRO) has given a return of -56.58% in the last 3 years.
Nevro Corp (NVRO) has a market capitalisation of $ 223 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Nevro Corp (NVRO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nevro Corp (NVRO) and enter the required number of quantities and click on buy to purchase the shares of Nevro Corp (NVRO).
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California. Address: 1800 Bridge Parkway, Redwood City, CA, United States, 94065
The CEO & director of Mr. Roderick H. MacLeod. is Nevro Corp (NVRO), and CFO & Sr. VP is Mr. Kevin R. Thornal.
There is no promoter pledging in Nevro Corp (NVRO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,103
|
|
|
1,084
|
|
|
1,055
|
|
|
990
|
| Nevro Corp. (NVRO) | Ratios |
|---|---|
|
Return on equity(%)
|
-43.28
|
|
Operating margin(%)
|
-34.35
|
|
Net Margin(%)
|
-27.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nevro Corp (NVRO) was $0 Mln.
